{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:44:31Z","timestamp":1794249871286,"version":"4.9.0"},"reference-count":111,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myelofibrosis (MF), Myeloproliferative neoplasms (MPNs), and MDS\/MPN overlap syndromes have a broad range of clinical presentations and molecular abnormalities, making their diagnosis and classification complex. This paper reviews molecular aberration, epigenetic modifications, chromosomal anomalies, and their interactions with cellular and other immune mechanisms in the manifestations of these disease spectra, clinical features, classification, and treatment modalities. The advent of new-generation sequencing has broadened the understanding of the genetic factors involved. However, while great strides have been made in the pharmacological treatment of these diseases, treatment of advanced disease remains hematopoietic stem cell transplant.<\/jats:p>","DOI":"10.3390\/ijms242417383","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T04:28:31Z","timestamp":1702355311000},"page":"17383","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape"],"prefix":"10.3390","volume":"24","author":[{"given":"Muftah","family":"Mahmud","sequence":"first","affiliation":[{"name":"Department of Medicine, Midwestern University Internal Medicine Residency Consortium, Cottonwood, AZ 86326, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Vasireddy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona Health Sciences, Tucson, AZ 85701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisstina","family":"Gowin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ 85701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-6056","authenticated-orcid":false,"given":"Akshay","family":"Amaraneni","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ 85701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood-2015-12-686402","article-title":"Some speculations on the myeloproliferative syndromes [editorial]. Blood. 1951;6(4):372-375","volume":"127","author":"Dameshek","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis biology and contemporary management","volume":"191","author":"Gangat","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00277-020-04055-w","article-title":"Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States","volume":"99","author":"Verstovsek","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1038\/leu.2017.268","article-title":"Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological Drivers of Clinical Phenotype in Myelofibrosis","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk. Lymphoma."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","article-title":"Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2008.001271","article-title":"Clinical relevance of JAK2 (V617F) mutant allele burden","volume":"94","author":"Passamonti","year":"2009","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100016","DOI":"10.1016\/j.modpat.2022.100016","article-title":"Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study","volume":"36","author":"Lake","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Easwar, A., and Siddon, A.J. (2021). Genetic landscape of myeloproliferative neoplasms with an emphasis on molecular diagnostic laboratory testing. Life, 11.","DOI":"10.3390\/life11111158"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression","volume":"22","author":"Adli","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/leu.2017.318","article-title":"Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: Phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: A FIM study","volume":"5","author":"Riou","year":"2021","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: Significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"key":"ref_32","first-page":"1","article-title":"SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)","volume":"136","author":"Zhao","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.hoc.2020.11.004","article-title":"The Role of Megakaryocytes in Myelofibrosis","volume":"35","author":"Migliaccio","year":"2021","journal-title":"Hematol. Oncol. Clin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.3706","article-title":"Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells","volume":"20","author":"Zhao","year":"2014","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI82905","article-title":"Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis","volume":"127","author":"Gilles","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-9440(10)62056-1","article-title":"Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis","volume":"167","author":"Vannucchi","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Farina, M., Bernardi, S., Polverelli, N., D\u2019adda, M., Malagola, M., Bosio, K., Re, F., Almici, C., Dunbar, A., and Levine, R.L. (2021). Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells, 10.","DOI":"10.3390\/cells10102764"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/bjh.17850","article-title":"The immune landscape in BCR-ABL negative myeloproliferative neoplasms: Inflammation, infections and opportunities for immunotherapy","volume":"196","author":"Strickland","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3109\/10428194.2013.764417","article-title":"Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis","volume":"54","author":"Skov","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1345402","DOI":"10.1080\/2162402X.2017.1345402","article-title":"Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis","volume":"6","author":"Romano","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41375-020-0909-7","article-title":"Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients","volume":"35","author":"Landtblom","year":"2021","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.17096","article-title":"Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms","volume":"193","author":"Alimam","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with Myeloid Metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","article-title":"Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients","volume":"75","author":"Visani","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary Myelofibrosis: 2023 update on diagnosis, riskstratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: Incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1002\/ajh.26362","article-title":"Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001\u20132017","volume":"96","author":"Dores","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ott, G., Hsi, E.D., Delabie, J., and Rodig, S. (2014). Principles of the pathology and biology of malignant lymphomas. Rare Lymphomas, 3\u201316.","DOI":"10.1007\/978-3-642-39590-1_1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/EDBK_320113","article-title":"Navigating Myelodysplastic and Myelodysplastic\/Myeloproliferative Overlap Syndromes","volume":"41","author":"Hasserjian","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12288-019-01084-y","article-title":"Myelodysplastic Syndrome\/Myeloproliferative Neoplasm (MDS\/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications","volume":"35","author":"Pati","year":"2019","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004\u201315","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"101195","DOI":"10.1016\/j.beha.2020.101195","article-title":"Molecular genetics of MDS\/MPN overlap syndromes","volume":"33","author":"Hunter","year":"2020","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cam4.1946","article-title":"Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia","volume":"8","author":"Faisal","year":"2019","journal-title":"Cancer Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"204062072092710","DOI":"10.1177\/2040620720927105","article-title":"A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant JAK2 V617F and SETBP1 mutations: A case report and literature review","volume":"11","author":"Gao","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group\u2019s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF\u2013dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V77.5.925.925","article-title":"Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors","volume":"77","author":"Emanuel","year":"1991","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/ped.13068","article-title":"Diagnosis and treatment of juvenile myelomonocytic leukemia","volume":"58","author":"Sakashita","year":"2016","journal-title":"Pediatr. Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2010.08525.x","article-title":"Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia","volume":"152","author":"Loh","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm\u2013unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"579221","DOI":"10.3389\/fonc.2020.579221","article-title":"Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic\/Myeloproliferative Neoplasms: A Meta-Analysis","volume":"10","author":"Wan","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)\u2014A study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wang, Z., Liu, W., Wang, D., Yang, E., Li, Y., Li, Y., Sun, Y., Wang, M., Lv, Y., and Hu, X. (2022). TET2 Mutation May Be More Valuable in Predicting Thrombosis in ET Patients Compared to PV Patients: A Preliminary Report. J. Clin. Med., 11.","DOI":"10.3390\/jcm11226615"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41379-021-00961-0","article-title":"Myelodysplastic\/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: A multi-institutional collaborative study from the Bone Marrow Pathology Group","volume":"35","author":"Orazi","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_84","first-page":"514\u2013523.e9","article-title":"Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms","volume":"28","author":"Escabi","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41591-022-01793-4","article-title":"In Utero Origin of Myelofibrosis Presenting in Adult Monozygotic Twins","volume":"28","author":"Sousos","year":"2022","journal-title":"Nat. Med."},{"key":"ref_86","first-page":"1","article-title":"Mechanism of action of hydroxyurea","volume":"19","author":"Yarbro","year":"1992","journal-title":"Semin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN","volume":"87","author":"Antonioli","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Kerguelen","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: Results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"Magro","year":"2017","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0038-1661206","article-title":"Inhibition of Platelet Production Induced by an Antiplatelet Drug, Anagrelide, in Normal Volunteers","volume":"52","author":"Andes","year":"1984","journal-title":"Thromb. Haemost."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11899-016-0335-0","article-title":"The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia","volume":"11","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1080\/10428190802087462","article-title":"GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia","volume":"49","author":"Rinaldi","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1038\/s41467-022-32694-2","article-title":"Paving the way to improve therapy for Myeloproliferative Neoplasms","volume":"13","author":"Bywater","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-022-29381-7","article-title":"Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms","volume":"13","author":"Saleiro","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Polverelli, N., Farina, M., D\u2019Adda, M., Damiani, E., Grazioli, L., Leoni, A., Malagola, M., Bernardi, S., and Russo, D. (2022). How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. Cells, 11.","DOI":"10.3390\/cells11030553"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"737951","DOI":"10.3389\/fmed.2021.737951","article-title":"Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations","volume":"8","author":"Meng","year":"2021","journal-title":"Front. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"20406207231177282","DOI":"10.1177\/20406207231177282","article-title":"Treating accelerated and blast phase myeloproliferative neoplasms: Progress and challenges","volume":"14","author":"Ajufo","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.hoc.2020.11.003","article-title":"The Microenvironment in Myeloproliferative Neoplasms","volume":"35","author":"Ramanathan","year":"2021","journal-title":"Hematol. Oncol. Clin."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/24\/17383\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:37:10Z","timestamp":1760132230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/24\/17383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":111,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242417383"],"URL":"https:\/\/doi.org\/10.3390\/ijms242417383","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]}}}